Article

Preventive effects of ulinastatin on acute respiratory distress syndrome

  • JIA Li-jing ,
  • YI Liang ,
  • YANG Zhi-xu ,
  • WANG Shu-peng ,
  • LI Gang ,
  • ZHU Xi
Expand
  • (1. ICU, Peking University Third Hospital, Beijing 100191, China; 2. ICU, Cangzhou People’s Hospital, Cangzhou 061000, Hebei, China; 3. ICU, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, China; 4. ICU, China-Japan Friendship Hospital, Beijing 100029, China)

Online published: 2016-08-18

Supported by

Supported by the National Natural Science Foundation of China (81372043), the Capital Medical Development and Scientific Research Fund (2009-1014), Beijing Natural Science Foundation (7162199), and Techpool Research Fund (01201113)

Abstract

Objective:To explore the effect of ulinastatin on prevention of acute respiratory distress syndrome (ARDS). Methods: A prospective multicentral cohort study was conducted. The patients from three intensive care units (ICUs) of grade A tertiary hospitals in Beijing and a ICU of grade A tertiary hospitals in Cangzhou from January 2012 to December 2014, included 77 ARDS atrisk patients with ulinastatin treatment and 108 ARDS atrisk patients without ulinastatin treatment (control) were eligible. Both groups received normal treatment; additionally, the intervention group received 600 000 units of ulinastatin via intravenous infusion for 5 days. The control group received the same amount of saline via intravenous infusion for 5 days. Venous blood human neutrophil elastase (HNE) and peptidase inhibitor 3 (PI3) levels were measured on days 1, 3, and 7, respectively. Other outcomes included acute physiology and chronic health evaluation scoring Ⅱ (APACHE Ⅱ), body temperature, respiratory rate, heart rate, mean arterial pressure, white blood cell counts, PaO2/FiO2, ARDS incident, mechanical ventilation time, ICU treatment and hospitalization duration, 28 days mortality.  Results: The PI3 levels showed no statistical difference on day 1, but significant differences on day 3 and day 7 between the two groups (P<0.01). HNE/PI3 ratio showed no statistical difference on day 1, but significant differences on day 3 and day 7 (P<0.05). PaO2/FiO2 was significantly higher in ulinastatin group on day 3 and day 7 (P<0.05). The incident rate for ulinastatin group was 15.58%, lower than that for the control group (33.33%), and the difference was statistically significant (P<0.05). The mechanical ventilation time and ICU treatment time in ulinastatin group was shorter than that in the control group, and the difference was statistically significant (P<0.05). There were no significant effects in other factors. Conclusion: Increased dose of ulinastatin can recover the balance of HNE and its antagonist, lower the HNE’s damage to lungs, and further reduce the ARDS incident rate.

Cite this article

JIA Li-jing , YI Liang , YANG Zhi-xu , WANG Shu-peng , LI Gang , ZHU Xi . Preventive effects of ulinastatin on acute respiratory distress syndrome[J]. Journal of Peking University(Health Sciences), 2016 , 48(4) : 672 -679 . DOI: 10.3969/j.issn.1671-167X.2016.04.021

Outlines

/